Lipid Screening Study

July 28, 2026 updated by: University of Central Florida

Prospective Screening for Elevated Lipoprotein(a) in an Adult Primary Care Population

The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.

Study Overview

Status

Completed

Conditions

Lipoprotein (a)

Intervention / Treatment

Other: Venipuncture

Study Type

Observational

Enrollment (Actual)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

United States
- Florida
  - Orlando, Florida, United States, 32827
    - University of Central Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

As any adult patient can be enrolled, no pre-screening will be done. UCFH only sees adult patients.

Description

Inclusion Criteria:

Adults aged 18 years or older
Receiving care at UCF Health primary care clinic
Able to understand and provide informed consent and HIPAA authorization

Exclusion Criteria:

Patient self discloses any medical condition that would make venipuncture unsafe
Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lipoprotein(a) prevalence in Adults Time Frame: 3 months	The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.	3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Central Florida

Investigators

Principal Investigator: Stephanie Perez, MSN, MBA, ARNP, CLS, BHCN, University of Central Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2026

Primary Completion (Actual)

July 16, 2026

Study Completion (Actual)

July 28, 2026

Study Registration Dates

First Submitted

May 6, 2026

First Submitted That Met QC Criteria